Vaccitech raises $27 million for the flu | January 22, 2018 Issue - Vol. 96 Issue 4 | Chemical & Engineering News
Volume 96 Issue 4 | p. 13 | Concentrates
Issue Date: January 22, 2018

Vaccitech raises $27 million for the flu

By Ryan Cross
Department: Business
Keywords: Vaccines, Vaccitech, Oxford, universal flu vaccine, flu, influenza

Oxford University spin-off company Vaccitech has raised $27.1 million in series A funding to advance its universal flu vaccine and cancer vaccine programs. The flu vaccine, based on proteins conserved across all influenza A strains, is currently in a Phase IIb trial with over 800 people. Programs for four other infectious diseases are in various stages of development, and a Phase II trial for a prostate cancer vaccine will begin this year. Investors include GV (formerly Google Ventures), Sequoia China, Oxford Sciences Innovation, and Neptune Ventures.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment